Boston Scientific Corporation stock page - price, fundamentals, dividends - iOCharts

BSX

44.47
+0.34 (0.77%)
Boston Scientific Corporation (NYSE, USD)
Healthcare >
Medical Devices
Market cap
63.17B
Ent value
76.34B
Price/Sales
6.37
Price/Book
4.02
Div yield
-
Div growth
-
Growth years
-
FCF payout
4.95%
Trailing P/E
-
Forward P/E
24.17
PEG
-
EPS growth
108.20%
1 year return
18.46%
3 year return
5.82%
5 year return
13.98%
10 year return
22.83%
Last updated: 2021-10-20

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open44.46
Daily high45.00
Daily low44.23
Daily Volume7.83M
All-time high45.88
1y analyst estimate48.97
Beta0.84
EPS (TTM)-0.06
Dividend per share-
Ex-div date-
Next earnings date27 Oct 2021

Downside potential

Loading...
Downside potential data
BSXS&P500
Current price drop from All-time high-3.07%-0.17%
Highest price drop-89.15%-56.47%
Date of highest drop26 Jul 20129 Mar 2009
Avg drop from high-43.58%-11.45%
Avg time to new high46 days12 days
Max time to new high4361 days1805 days

DIVIDENDS

BSX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF41.89
Price to FCF55.80
Price to EBITDA33.66
EV to EBITDA40.67

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales6.37
Price to Book4.02
EV to Sales7.70

FINANCIALS

Per share

Loading...
Per share data
Current share count1.42B
EPS (TTM)-0.06
FCF per share (TTM)0.80

Income statement

Loading...
Income statement data
Revenue (TTM)9.91B
Gross profit (TTM)6.45B
Operating income (TTM)684.00M
Net income (TTM)-81.00M
EPS (TTM)-0.06
EPS (1y forward)1.84

Margins

Loading...
Margins data
Gross margin (TTM)65.04%
Operating margin (TTM)6.90%
Profit margin (TTM)-0.82%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.02B
Net receivables1.63B
Total current assets6.10B
Goodwill10.87B
Intangible assets5.99B
Property, plant and equipment2.46B
Total assets30.90B
Accounts payable2.67B
Short/Current long term debt9.08B
Total current liabilities3.39B
Total liabilities15.18B
Shareholder's equity15.72B
Net tangible assets-1.14B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)1.51B
Capital expenditures (TTM)376.00M
Free cash flow (TTM)1.13B
Dividends paid (TTM)56.00M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-0.53%
Return on Assets-0.26%
Return on Invested Capital-0.33%
Cash Return on Invested Capital4.63%
COMPANY DETAILS
BSX (Boston Scientific Corporation) company logo
Marketcap
63.17B
Marketcap category
Large-cap
Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Employees
38000
SEC filings
CEO
Michael Mahoney
Country
USA
City
Marlborough
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.
October 21, 2021
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
October 20, 2021
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
October 19, 2021
In this article, we will be taking a look at the 10 healthcare stocks to buy according to billionaire Noam Gottesman’s GLG Partners. If you want to skip our detailed analysis about the fund and its ow...
October 19, 2021
The Baylis Medical buyout is expected to expand Boston Scientific's (BSX) electrophysiology and structural heart product offerings.
October 14, 2021
In this article, we will discuss the top 10 new stocks for 2021 to buy now according to Qing Li’s Sciencast Management portfolio. If you want to skip our detailed analysis of Li’s history, investment ...
October 13, 2021
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
October 12, 2021
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.
October 11, 2021
Boston Scientific Corporation (BSX), the manufacturer of medical devices used in interventional medical specialties, announced that it has signed a deal to snap up Baylis Medical Company Inc. for $1.7...
October 7, 2021
Boston Scientific Corporation (NYSE: BSX) has announced data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) at the Vascular InterVentional Advances meeting. Data presented included o...
October 6, 2021
Next page